Genentech Oncology
This compound and its use are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
The ER is a ligand-sensitive transcription factor expressed in various tissues, including the breast, where it can drive ER+ tumor cell division.1
The activating ligand estrogen enters the cell and binds to the ligand-binding domain of the ER, promoting the dynamic association of the ER with specific regions of DNA.1 Hotspot mutations in the ER (eg, Y537S and D538G) allow for estrogen-independent activation of the ER.2-4
The activated ER triggers the expression of numerous target genes, including cyclin D1 (CCND1), which regulates the activity of cyclin-dependent kinases 4 and 6 (CDK4/6), and the progesterone receptor (PGR).5,6
The gene expression program activated by the ER promotes ER+ tumor growth by driving cell proliferation.1
Giredestrant, an investigational small molecule, is a full ER antagonist belonging to the SERD class of therapeutics.7,8
Preclinical studies suggest that Giredestrant is orally bioavailable and competitively inhibits the binding of estrogen to the ER.7,9
In preclinical models, Giredestrant has been shown to restrain the normally dynamic behavior of both wild-type and mutant ER, immobilizing the ER and attenuating the expression of its target genes.7,9,10 The ER is subsequently degraded by the proteasome, which may lead to a reduction in ER protein level without completely eliminating it.7,9
In preclinical models, Giredestrant demonstrates inhibition of the ER-induced proliferative program and suppression of tumor growth.7,9
As with other SERDs, the addition of CDK4/6 inhibitors may potentially enhance the antiproliferative effect of Giredestrant in ER+ breast cancer cells.11
Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225-240. PMID: 23043248
Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225-240. PMID: 23043248
Metcalfe C, Friedman LS, Hager JH. Hormone-targeted therapy and resistance. Annu Rev Cancer Biol. 2018;2:291-312.
Metcalfe C, Friedman LS, Hager JH. Hormone-targeted therapy and resistance. Annu Rev Cancer Biol. 2018;2:291-312.
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445. PMID: 24185512
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445. PMID: 24185512
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-1451. PMID: 24185510
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-1451. PMID: 24185510
O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18(8):1859-1875. PMID: 15031323
O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18(8):1859-1875. PMID: 15031323
Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220(2):292-296. PMID: 19415697
Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220(2):292-296. PMID: 19415697
Metcalfe C, Ingalla E, Blake RA, et al. Poster presented at the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract P5-04-07.
Metcalfe C, Ingalla E, Blake RA, et al. Poster presented at the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract P5-04-07.
Jhaveri K, Winer EP, Lim E, et al. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract PD7-05.
Jhaveri K, Winer EP, Lim E, et al. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract PD7-05.
Wang X. Presented at 2020 American Association for Cancer Research Virtual Annual Meeting I; April 22-27, 2020. Abstract DDT02-05.
Wang X. Presented at 2020 American Association for Cancer Research Virtual Annual Meeting I; April 22-27, 2020. Abstract DDT02-05.
Guan J, Zhou W, Hafner M, et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell. 2019;178(4):949-963.e18. PMID: 31353221
Guan J, Zhou W, Hafner M, et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell. 2019;178(4):949-963.e18. PMID: 31353221
Iorfida M, Mazza M, Munzone E. Fulvestrant in combination with CDK4/6 inhibitors for HER2- metastatic breast cancers: current perspectives. Breast Cancer (Dove Med Press). 2020;12:45-56. PMID: 32256106
Iorfida M, Mazza M, Munzone E. Fulvestrant in combination with CDK4/6 inhibitors for HER2- metastatic breast cancers: current perspectives. Breast Cancer (Dove Med Press). 2020;12:45-56. PMID: 32256106
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.